Mandate

Vinge represents HealthCap and Wilson Therapeutics AB in private placement

May 22, 2014

Wilson Therapeutics AB has completed a private placement of USD 40,000,000 (SEK 260,000,000) directed to the venture capital firms Abingworth LLP and MVM Life Science Partners LLP and the existing investor HealthCap.

Wilson Therapeutics AB is a life science company focused on the development of drugs for the treatment of Wilson’s Disease, a rare genetic disease that affects approximately 1 in 15,000 people worldwide. The private placement is conducted to finance further product development, clinical trials and commercialisation of the company’s products.

Vinge represented HealthCap and Wilson Therapeutics AB in the private placement and Vinge’s team consisted of partner Jesper Ottergren together with, among others, Kristian Ford and Karin Engström.

Related

Vinge has assisted KMC Properties in its merger with Logistea

On June 14, 2024, KMC Properties ASA, listed on Oslo Børs, announced that the company is merging with Logistea AB (publ), listed on Nasdaq Stockholm.
June 24, 2024

Vinge advises Cinclus Pharma in connection with listing on Nasdaq Stockholm

Vinge advises Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) in connection with an offering of new ordinary shares and listing on Nasdaq Stockholm. The first day of trading is 20 June 2024.
June 20, 2024

Vinge advises Axcel VI and the Currentum in connection with the acquisition of Elektro-Emanuel

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elektro-Emanuel AB. The company carries out electrical installations for both companies and private individuals and has offices in four cities in western Sweden.
June 19, 2024